Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

The Real Peptides Protocol for Diluting BPC 157

When you're engaged in serious research, precision isn't just a goal; it's the entire foundation. Every variable, every measurement, every single step contributes to the validity of your final data. This is especially true in the world of peptide research, whe

When you're engaged in serious research, precision isn't just a goal; it's the entire foundation. Every variable, every measurement, every single step contributes to the validity of your final data. This is especially true in the world of peptide research, where the integrity of your materials can make or break a study. And honestly, one of the most frequently overlooked—yet absolutely critical—steps is the initial preparation of the peptide itself. We're talking about how to dilute BPC 157.

It might seem like a simple task, just adding water to a powder. But it's far more nuanced than that. The process, known as reconstitution, is a meticulous scientific procedure. Getting it wrong can lead to inaccurate dosing, degraded compounds, and ultimately, compromised research outcomes. Our team at Real Peptides has spent years perfecting the synthesis of high-purity research compounds like our BPC 157 Peptide, and we believe that providing guidance on its proper handling is part of our commitment to scientific excellence. This isn't just a set of instructions; it's the protocol we've refined to ensure the materials you work with maintain the impeccable purity they had when they left our lab.

Why Proper Dilution is a Non-Negotiable First Step

Let's get straight to the point. The lyophilized BPC 157 you receive is in a delicate, stable, powdered state for a reason. Lyophilization, or freeze-drying, removes water from the peptide under low pressure, which preserves its complex structure and ensures its long-term stability during shipping and storage. It’s a sophisticated process for a sophisticated molecule.

But in this state, it's unusable for research. It needs to be reconstituted into a liquid solution. This is where the risks come into play. The moment you introduce a liquid, you're changing the peptide's environment and starting a countdown on its stability. The type of liquid you use, the way you introduce it, and how you handle the vial afterward are all pivotal factors. Using the wrong solvent can instantly damage the peptide's fragile amino acid chains. Shaking the vial instead of gently rolling it can shear the proteins apart through mechanical force. We can't stress this enough: improper reconstitution can render a high-purity peptide completely useless.

Think of it this way: you wouldn't build a precision-engineered race car and then fill it with contaminated fuel. It's the same principle. The entire potential of your research hinges on preserving the integrity of the compound from the very beginning. Every subsequent data point you collect is downstream from this initial step. If the dilution is flawed, the entire experiment is flawed. It’s that simple.

Our experience shows that researchers who master this fundamental process achieve more consistent and reliable results. It's a discipline. It’s about respecting the science and the materials. So, before you even think about calculations or drawing a dose, you need the right tools for the job.

Assembling Your Lab-Grade Toolkit

Setting up for success means having the correct supplies on hand before you begin. Trying to improvise here is a recipe for contamination or inaccurate measurements. This isn't the time to cut corners. Here's what our team considers the essential, non-negotiable toolkit for reconstituting BPC 157.

Your Vial of Lyophilized BPC 157: This is your starting point. At Real Peptides, our BPC 157 Peptide comes in a sealed vial, ensuring it remains sterile and protected until you're ready to use it.

Bacteriostatic Water: This is the most critical component next to the peptide itself. Bacteriostatic Water, or BAC water, is sterile water that contains 0.9% benzyl alcohol. This alcohol acts as a preservative, preventing the growth of bacteria inside the vial after it's been reconstituted. This is profoundly important because you'll likely be piercing the rubber stopper multiple times to draw doses. Using plain sterile water doesn't offer this protection, dramatically shortening the usable life of your peptide and introducing a significant risk of contamination.

An Insulin Syringe for Measurement: A 1ml (or 1cc) insulin syringe is the standard tool for this process. They are marked in Units (U), typically up to 100, which makes measuring small, precise volumes of liquid straightforward. You'll use one syringe for adding the BAC water and a new, sterile syringe for each dose you draw for your research.

Alcohol Prep Pads: Sterility is paramount. You must use alcohol pads to wipe the rubber stoppers on both the BPC 157 vial and the BAC water vial before piercing them with a needle. This simple act removes any surface contaminants and is a fundamental part of good lab practice.

Here's a quick comparison of reconstitution liquids, which really underscores why BAC water is the industry standard for this kind of work.

Bacteriostatic Water

Contains 0.9% benzyl alcohol

Yes

Gold Standard for multi-use peptide vials. Preserves sterility.

Sterile Water

Pure, sterile H2O

No

Suitable only for single-use applications where the entire vial is used at once.

Saline Solution

Sterile water with sodium chloride

Generally not recommended for initial reconstitution as it can affect peptide solubility and stability.

Tap or Bottled Water

Non-sterile, contains minerals/contaminants

Absolutely not. Will contaminate and likely destroy the peptide.

As you can see, the choice is clear. For any research protocol that requires drawing multiple doses from the same vial over time, bacteriostatic water is the only acceptable option.

The Math Behind Dilution: Making it Painless

Alright, let's tackle the math. This is where many people feel intimidated, but the calculations are actually very straightforward once you understand the relationship between the components. We're going to walk through a common scenario to make it crystal clear.

Scenario: You have a 5mg vial of BPC 157 and you want to be able to dose it in microgram (mcg) increments.

Step 1: Understand the UnitsFirst, you need to be comfortable with the units. The most important conversion is milligrams (mg) to micrograms (mcg).

1 milligram (mg) = 1,000 micrograms (mcg)

Therefore, your 5mg vial of BPC 157 contains 5,000mcg of the peptide.

Step 2: Choose Your Water VolumeThe amount of BAC water you add determines the final concentration of your solution. Adding more water makes the solution less concentrated (more diluted), and adding less water makes it more concentrated. For ease of dosing, we often recommend using a simple volume like 1mL or 2mL.

Let's use 2mL of BAC water for our example. A 1mL insulin syringe is typically marked with 100 units. So, 2mL is equal to two full insulin syringes (200 units).

Step 3: Calculate the ConcentrationNow you just need to figure out how much BPC 157 is in each unit or tick mark on your syringe. The formula is simple:

Total Peptide (in mcg) / Total Volume (in units) = mcg per unit

Using our example:

5,000mcg of BPC 157 / 200 units (which is 2mL) = 25mcg per unit

This means that every single tick mark on your 1mL insulin syringe will now contain 25mcg of BPC 157. Simple, right?

What if you used 1mL of water instead?Let's run the numbers to see how it changes.

5,000mcg of BPC 157 / 100 units (which is 1mL) = 50mcg per unit

See the difference? Using less water creates a more concentrated solution. Neither is right or wrong; it's about what makes the dosing math easiest and most accurate for your specific research protocol. Our team generally finds that a slightly more diluted solution (like using 2mL of water) allows for finer control over smaller doses and reduces the margin for error.

The Meticulous Step-by-Step Reconstitution Protocol

With your supplies gathered and your calculations done, it's time for the procedure itself. Approach this like a surgeon: clean, calm, and precise. Rushing leads to mistakes.

Step 1: Prepare Your WorkspaceDesignate a clean, flat surface. Wipe it down. Wash your hands thoroughly. Lay out your supplies: the BPC 157 vial, the BAC water vial, a sealed insulin syringe, and several alcohol pads.

Step 2: Prep the VialsPop the plastic protective caps off both the BPC 157 and BAC water vials. Don't assume the rubber stoppers underneath are sterile. Take an alcohol pad and vigorously wipe the top of each stopper. Let them air dry for a moment.

Step 3: Draw the Bacteriostatic WaterUncap your insulin syringe. Pull the plunger back to the mark that corresponds to the volume you calculated. In our example, we're using 2mL, so you would first pull the plunger back to the 100-unit mark (1mL) to draw in air. This is important—you need to inject air into the BAC water vial to equalize the pressure, making it easier to draw the liquid out.

Insert the needle through the center of the BAC water's rubber stopper. Push the plunger down, injecting the air into the vial. Then, turn the vial upside down and slowly pull the plunger back to draw out 1mL (100 units) of BAC water. Remove the syringe.

If your calculation called for 2mL, you'll need to repeat this process with a second 1mL draw. For accuracy, it's better to do two precise 1mL draws than one less-precise 2mL draw from a larger syringe.

Step 4: Introduce the Water to the BPC 157This is the most delicate part of the process. Take your syringe filled with BAC water and insert the needle through the rubber stopper of the BPC 157 vial. Here's the key: do not inject the water directly onto the lyophilized powder. This can damage the peptide.

Instead, angle the needle so the stream of water runs slowly down the inside wall of the glass vial. Push the plunger gently and steadily until all the water has been added. The water will pool at the bottom and begin dissolving the powder.

Step 5: Gentle Mixing (No Shaking!)Once the water is in, remove the syringe. Now, you need to ensure the powder dissolves completely. We cannot repeat this enough: DO NOT SHAKE THE VIAL. Shaking creates foam and can destroy the peptide chains through mechanical stress.

Instead, gently roll the vial between your fingers or palms. You can also lightly swirl it. The powder should dissolve quite easily, resulting in a clear liquid. If you see any undissolved particles, continue to gently roll it until the solution is completely transparent.

Your BPC 157 is now reconstituted and ready for research use.

From Vial to Syringe: Calculating Your Precise Dose

Now that you have a reconstituted solution with a known concentration, drawing an accurate dose is simple.

Let's continue with our example where our solution has a concentration of 25mcg per unit.

Imagine your research protocol calls for a dose of 250mcg.

The formula is:

Desired Dose (in mcg) / Concentration (in mcg per unit) = Number of Units to Draw

So, for our example:

250mcg / 25mcg per unit = 10 units

You would take a new, sterile insulin syringe, insert it into the reconstituted BPC 157 vial (after wiping the stopper with alcohol again, of course), and slowly draw the liquid until the top of the black plunger is perfectly aligned with the 10-unit mark on the syringe barrel.

That's it. You have an accurate 250mcg dose ready for your experiment.

Critical Storage and Handling for Longevity

Reconstitution begins the countdown clock on your peptide's viability. Proper storage is not optional; it's essential for preserving the compound's integrity for the duration of your study.

Before Reconstitution: The lyophilized, powdered BPC 157 is quite stable. You can store it in a cool, dark place. For long-term storage (months), refrigeration is best, but it's not strictly necessary for short periods. Some researchers even store it in the freezer, which is perfectly acceptable.

After Reconstitution: This is where the rules become strict. The liquid solution MUST be refrigerated immediately. Keep it in the main body of the refrigerator, not in the door where temperatures fluctuate. A stable temperature between 2°C and 8°C (36°F and 46°F) is ideal.

When stored properly in the refrigerator, a reconstituted vial of BPC 157 will typically remain potent and sterile for approximately 4 weeks. Beyond this point, the risk of degradation and bacterial contamination increases, even with BAC water.

Also, protect the vial from direct light, as UV light can degrade peptides over time. Keeping it in its original box or a small container within the fridge is a good practice.

Sidestepping Common Research Pitfalls

Over the years, our team has heard from countless researchers, and we've seen a few common mistakes pop up time and again. Avoiding these is key to good practice.

The Cardinal Sin: Shaking the Vial. We've mentioned it multiple times, but it bears repeating. Shaking is destructive. Always roll or swirl gently.

Using the Wrong Water. Using tap water, bottled water, or even plain sterile water (for a multi-use vial) is a catastrophic error that introduces contaminants and compromises the entire vial.

Math Errors. Double-check and even triple-check your calculations. A simple decimal point error can throw off your entire dosing schedule and invalidate your research. Write it down before you start.

Poor Sterile Technique. Reusing syringes or failing to wipe the stoppers with alcohol introduces bacteria. Each dose should be drawn with a fresh, sterile syringe.

Improper Storage. Leaving the reconstituted vial out at room temperature for extended periods will rapidly degrade the peptide. It must live in the refrigerator.

Avoiding these simple mistakes is what separates sloppy science from professional, repeatable research.

It All Starts with Purity

Ultimately, you can follow every step of this protocol with impeccable precision, but if the peptide you start with is of low quality, your efforts are wasted. The most flawless reconstitution technique cannot fix an impure or improperly synthesized compound. That's why we founded Real Peptides.

Our commitment is to provide the research community with materials of unwavering quality. We achieve this through small-batch synthesis, ensuring every vial meets our stringent standards for purity and exact amino-acid sequencing. This guarantees that when you learn how to dilute BPC 157 using our products, you're starting with the most reliable material possible. Your research deserves a foundation of certainty, and that's what we deliver.

This same dedication to quality applies across our entire catalog, from foundational peptides like BPC 157 and TB-500 to more specialized research compounds. We encourage you to explore our full collection of peptides to see how our commitment to purity can support the ambitious goals of your work.

Precision in the lab isn't just about following steps; it's a mindset. It's an understanding that every detail matters, from the quality of your source materials to the careful swirl of a vial. By mastering this fundamental process, you're not just preparing a peptide; you're setting the stage for credible, impactful discovery. Get Started Today on your next research project with the confidence that comes from quality materials and proper technique.

Frequently Asked Questions

Shaking the vial can cause mechanical stress that shears the delicate peptide bonds, potentially degrading the compound and reducing its effectiveness for research. If you’ve shaken it vigorously, the integrity of the solution may be compromised.

You should only use sterile water if you plan to use the entire contents of the vial in a single application. For multi-use vials, bacteriostatic water is essential as its benzyl alcohol content prevents bacterial growth from repeated needle punctures.

When properly reconstituted with bacteriostatic water and continuously stored in a refrigerator (not the door), BPC 157 solution is generally considered stable and sterile for about 4 weeks. Beyond that, its potency may begin to decline.

No, the total amount of peptide in the vial remains the same. Adding more or less water only changes the solution’s concentration—that is, how much peptide is in each milliliter or unit. It simply makes the solution more or less diluted.

Lyophilization is a freeze-drying process that removes water from the peptide to make it a stable, transportable powder. This process preserves the peptide’s structure and integrity for long-term storage until it’s ready to be reconstituted for use.

Tap and bottled water are non-sterile and contain minerals, chemicals, and microorganisms. Introducing them to a research-grade peptide would immediately contaminate it, likely destroying the compound and rendering it completely unusable for any valid study.

No, a properly reconstituted BPC 157 solution should be perfectly clear. If your solution is cloudy or has visible floating particles after gentle mixing, it may indicate a problem with the peptide’s solubility or potential contamination.

Store the vial in the main body of the refrigerator where the temperature is most stable. Avoid storing it in the refrigerator door, as the temperature fluctuates significantly every time the door is opened, which can accelerate degradation.

Yes, absolutely. For sterility and research accuracy, you must use a new, sterile syringe every time you draw a dose from the vial. Reusing syringes is a primary cause of contamination and can compromise your entire batch.

If you realize you’ve made a calculation error, it’s best to stop and recalculate everything before proceeding. If you’ve already added the wrong amount of water, you must adjust your dosing calculations accordingly to ensure you’re drawing the correct amount of peptide for your research.

No, never inject the water stream directly onto the lyophilized powder. The force can damage the fragile peptide. Always angle the needle so the water runs gently down the inside wall of the vial.

Our team strongly advises against pre-loading syringes for long-term storage. Peptides can be less stable in plastic syringes compared to glass vials, and the risk of contamination increases. It is always best practice to draw each dose immediately before application.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Frequency Options

Micro-dosing protocols vary in administration frequency. The short half-life of BPC-157 (less than 30 minutes) suggests frequent dosing might optimize tissue levels, yet the peptide initiates cellular processes that continue after clearance. Several approaches work effectively: Once Daily Protocol: A single morning dose of 0.1 to 0.15 mg provides simplicity and good results for most chronic conditions. This approach minimizes injection frequency while maintaining therapeutic benefit. Twice Daily Protocol: Splitting the daily dose into morning and evening administrations (0.05 to 0.075 mg each) maintains more consistent tissue levels. Some individuals report better results with this approach, particularly for GI conditions. Five Days On, Two Days Off: This cycling pattern within each week may help maintain receptor sensitivity during extended protocols. The weekend break allows receptor resensitization while the consistent weekday dosing provides therapeutic benefit. BPC-157 does not develop traditional tolerance since it operates non-hormonally and does not suppress natural production. Unlike hormonal compounds, no post-cycle therapy is required and no rebound effects occur when discontinuing use.
STORAGE

Peptide Structure and Stability

The molecular structure of BPC-157 comprises 15 amino acids arranged in a specific sequence that confers exceptional stability under physiological conditions. This pentadecapeptide demonstrates resistance to degradation in gastric juice, a property that distinguishes it from many therapeutic peptides that require modified administration routes to avoid gastric inactivation. The peptide's stability profile allows for both oral and parenteral administration, with documented biological activity through multiple delivery routes including subcutaneous, intramuscular, intraperitoneal, and oral administration. Pharmacokinetic studies in rats and beagle dogs reveal that BPC-157 exhibits linear pharmacokinetic characteristics across all tested doses. Following single administration, the elimination half-life of prototype BPC-157 was less than 30 minutes in both species, indicating rapid systemic clearance. The mean absolute bioavailability following intramuscular injection was approximately 14-19% in rats and 45-51% in beagle dogs, suggesting species-specific absorption characteristics relevant for dose translation to human applications. The metabolic pathway of BPC-157 involves rapid breakdown into various small peptide fragments in vivo, ultimately forming single amino acids that enter normal amino acid metabolism and excretion pathways. Radiolabeled [3H]BPC-157 studies demonstrate that the peptide is finally metabolized into single amino acids, represented primarily by proline, in…
02

Question drills

Open a question for its connected answer.

01What If I'm Using BPC-157 for an Old Scar—Can It Remodel Mature Tissue?+

No meaningful remodeling occurs in scars older than 12–18 months. Mature scar tissue has completed collagen crosslinking and vascular regression—the biological processes BPC-157 modulates are no longer active. The peptide accelerates healing in acute injuries and reduces scarring during active repair, but it doesn't reverse fibrotic tissue once maturation is complete. For old scars, laser resurfacing or microneedling to re-initiate controlled inflammation may offer better outcomes than peptide therapy alone.

SOURCE / realpeptides.co ↗
02What If Bacterial Translocation Is the Primary Concern?+

Prioritise barrier restoration over symptom management. Bacterial translocation occurs when tight junction failure allows gut bacteria or their endotoxins to cross into systemic circulation. Triggering sepsis risk, chronic low-grade inflammation, and immune activation. BPC-157 studied intestinal permeability in ischemia-reperfusion models reduced translocation to mesenteric lymph nodes by 65%, a functional outcome that reflects actual barrier sealing rather than just reduced inflammation. If translocation is documented or suspected, peptides targeting structural repair are mechanistically more relevant than immunosuppressants alone.

SOURCE / realpeptides.co ↗
03What If BPC-157 Research Translates to Human Diabetic Neuropathy Treatment?+

Translation would require Phase I dose-finding studies to establish human pharmacokinetics, followed by Phase II efficacy trials measuring nerve conduction velocity and patient-reported pain outcomes over 12–24 weeks. The challenge is that preclinical models use controlled hyperglycemia in otherwise healthy young rats. Human diabetic neuropathy involves decades of metabolic dysfunction, multiple comorbidities (hypertension, dyslipidemia, kidney disease), and polypharmacy that complicates interpretation. If BPC-157's angiogenic mechanism proves clinically relevant, it would represent the first therapy targeting microvascular insufficiency rather than just symptom management, but regulatory approval timelines would span 8–12 years minimum.

SOURCE / realpeptides.co ↗
04What If You Use Oral Administration for Post-Cycle Research?+

Oral BPC-157 works systemically but doesn't achieve the local tissue concentration that subcutaneous or intramuscular injection provides immediately post-injury. Post-cycle research benefits from direct delivery to damaged tissue where VEGF signaling and macrophage recruitment are localized. Oral administration pre-cycle leverages gastric receptor activation for systemic priming, but post-injury, bypassing first-pass metabolism with injection ensures higher peptide availability exactly where inflammatory resolution is needed.

SOURCE / realpeptides.co ↗
05What If the Cloudiness Partially Clears But Some Haziness Remains?+

Partial clearing after 30 minutes of refrigeration suggests mixed mechanisms. Some reversible aggregation alongside low-level precipitation or early-stage degradation. If the solution progresses from opaque to translucent but never reaches crystal clarity, err on the side of caution and discard it. 'Almost clear' is not functionally equivalent to 'clear' for peptides; residual haziness indicates insoluble material that won't contribute to biological activity and may cause injection site irritation. Our standard is unambiguous: if you can read newsprint text through the vial at arm's length, it's clear. If you can't, it's not.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

BPC-157 Studied Tennis Elbow — Recovery Research Explained

Fewer than 30% of lateral epicondylitis cases resolve with conservative treatment within six months. Physical therapy, rest, and NSAIDs address symptoms but not the underlying tendon pathology. BPC-157 studied tennis elbow as a regenerative compound because it acts on growth factor signaling pathways NSAIDs don't reach: it upregulates VEGF (vascular endothelial growth factor), accelerates collagen cross-linking, and supports Type-1 collagen deposition directly at the injury site. Our team works with research institutions using peptides for tendon and ligament studies. The gap between anecdotal athlete reports and controlled research comes down to three mechanistic actions most supplement marketing never mentions. What does BPC-157 studied tennis elbow research show about peptide-based tendon repair? BPC-157 studied tennis elbow in animal models demonstrated 40–60% faster tendon healing compared to controls, primarily through increased fibroblast migration and collagen synthesis at injury sites. The peptide, a synthetic derivative of body protection compound isolated from gastric juices, functions as a stable 15-amino-acid sequence resistant to gastric degradation. Human trials remain limited but early clinical observations suggest comparable tissue repair acceleration when administered via subcutaneous injection near affected tendons. Yes, BPC-157 studied tennis elbow specifically because lateral epicondylitis represents a failure of tendon remodeling. Not just inflammation. Standard anti-inflammatory protocols (corticosteroid injections, NSAIDs) suppress the pain cascade but also inhibit the collagen synthesis required for structural repair. BPC-157 operates through a different pathway: it enhances angiogenesis (new blood vessel formation) in hypovascular tendon tissue while simultaneously modulating inflammatory cytokines without suppressing the regenerative response. This article covers the exact mechanism by which BPC-157 studied tennis elbow cases differ from traditional approaches, what dosing protocols appear in peer-reviewed literature, and why injection site placement matters more than most protocols acknowledge.

RESEARCH

The Uncomfortable Truth About Chronic Infection Peptide Research

Here's the honest answer: BPC-157 and LL-37 aren't miracle cures, and the research community doesn't present them that way. They're tools for addressing specific failures in chronic infection pathophysiology. Impaired angiogenesis and biofilm persistence. That standard antibiotics don't target. The evidence for their combined use is compelling in preclinical models, but clinical translation remains years away because chronic infection trials require long follow-up periods and large sample sizes to detect meaningful differences from standard care. What frustrates researchers most is the gap between in vitro brilliance and in vivo complexity. LL-37 obliterates biofilms in petri dishes, but human wound environments contain proteases that degrade peptides, pH fluctuations that affect activity, and comorbidities (diabetes, immunosuppression) that complicate healing regardless of intervention. BPC-157 accelerates angiogenesis in healthy tissue, but chronic wounds often have underlying vascular disease that peptide therapy alone cannot reverse. The research value lies in mechanistic clarity. These peptides define why chronic infections persist and which specific molecular pathways must be restored for resolution. That knowledge matters even if the peptides themselves prove insufficient as standalone therapies. Our experience reviewing protocols from institutions studying BPC-157 LL-37 for chronic infection research shows consistent mechanistic validation. The pathways work as hypothesized. But outcome variability remains high because infection resolution depends on dozens of variables beyond peptide activity. The peptides used in these studies must meet strict purity standards to produce reproducible results. Our full peptide collection includes both BPC-157 and LL-37 synthesized under cGMP protocols with third-party HPLC verification. The quality threshold research institutions require for infection model work. Small-batch synthesis allows precise amino-acid sequencing, which matters because even single-residue substitutions can eliminate peptide activity entirely. If your research involves chronic wound infections or biofilm-associated pathogens, the combined protocol framework offers mechanistic advantages no single intervention provides. Whether that translates to clinical superiority depends on variables specific to each infection context. Host immune status, pathogen virulence, tissue oxygen levels, and comorbid conditions all influence outcomes independent of peptide efficacy. The science supports their use as research tools. The clinical evidence remains incomplete.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Gastric Protection Results Timeline Expect: Comparison

BPC-157 VEGF/FGF upregulation, angiogenesis, NOS modulation 3–7 days (mucosa stabilisation) 14–28 days (epithelial closure) Unknown. Limited long-term human data Most direct pro-r…